The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Book Review
PreviousPrevious
Volume 334:609-610 February 29, 1996 Number 9
NextNext

Science, Politics, and the Pharmaceutical Industry: Controversy and bias in drug regulation

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
By John Abraham. 308 pp. New York, St. Martin's Press, 1995. $49.95. ISBN 0-312-12873-8.

Since 1962, when Congress required proof of the efficacy and safety of drugs approved by the Food and Drug Administration (FDA), the FDA's summary opinions have been fairly consistent with those of the medical profession, as outlined in pharmacology textbooks. When the FDA arouses public wrath, it is often for moving more slowly than its European counterparts. Yet, according to John Abraham, a sociologist at the University of Reading in England, the story is not so simple. His book about testing drugs for efficacy and safety in the United States and the United Kingdom is illustrated by case histories and . . . [Full Text of this Article]




HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.